Cary Cynthia D, Lukovsky-Akhsanov Nicole L, Gallardo-Romero Nadia F, Tansey Cassandram M, Ostergaard Sharon D, Taylor Willie D, Morgan Clint N, Powell Nathaniel, Lathrop George W, Hutson Christina L
Comparative Medicine Branch, Centers for Disease Control and Prevention, Atlanta, Georgia;, Email:
Comparative Medicine Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
J Am Assoc Lab Anim Sci. 2017 Mar 1;56(2):160-165.
In this study, we evaluated the pharmacokinetic profiles of meloxicam and sustained-release (SR) buprenorphine in prairie dogs. The 4 treatment groups were: low-dose meloxicam (0.2 mg/kg SC), high-dose meloxicam (4 mg/kg SC), low-dose buprenorphine SR (0.9 mg/kg SC), and high-dose buprenorphine SR (1.2 mg/kg SC). The highest plasma concentrations occurred within 4 h of administration for both meloxicam treatment groups. The therapeutic range of meloxicam in prairie dogs is currently unknown. However, as compared with the therapeutic range documented in other species (0.39 - 0.91 μg/mL), the mean plasma concentration of meloxicam fell below the minimal therapeutic range prior to 24 h in the low-dose group but remained above therapeutic levels for more than 72 h in the high-dose group. These findings suggest that the current meloxicam dosing guidelines may be subtherapeutic for prairie dogs. The highest mean plasma concentration for buprenorphine SR occurred at the 24-h time point (0.0098 μg/mL) in the low-dose group and at the 8-h time point (0.015 μg/mL) for the high-dose group. Both dosages of buprenorphine SR maintained likely plasma therapeutic levels (0.001 μg/mL, based on previous rodent studies) beyond 72 h. Given the small scale of the study and sample size, statistical analysis was not performed. The only adverse reactions in this study were mild erythematous reactions at injection sites for buprenorphine SR.
在本研究中，我们评估了美洛昔康和缓释丁丙诺啡在草原犬鼠体内的药代动力学特征。4个治疗组分别为：低剂量美洛昔康（0.2毫克/千克皮下注射）、高剂量美洛昔康（4毫克/千克皮下注射）、低剂量缓释丁丙诺啡（0.9毫克/千克皮下注射）和高剂量缓释丁丙诺啡（1.2毫克/千克皮下注射）。两个美洛昔康治疗组在给药后4小时内出现最高血浆浓度。目前尚不清楚美洛昔康在草原犬鼠体内的治疗范围。然而，与其他物种记录的治疗范围（0.39 - 0.91微克/毫升）相比，低剂量组美洛昔康的平均血浆浓度在24小时前降至最低治疗范围以下，但高剂量组在72小时以上仍保持在治疗水平之上。这些发现表明，目前的美洛昔康给药指南对草原犬鼠可能达不到治疗效果。低剂量组缓释丁丙诺啡的最高平均血浆浓度出现在24小时时间点（0.0098微克/毫升），高剂量组出现在8小时时间点（0.015微克/毫升）。两种剂量的缓释丁丙诺啡在72小时后均维持了可能的血浆治疗水平（基于先前的啮齿动物研究，为0.001微克/毫升）。鉴于本研究规模小和样本量有限，未进行统计分析。本研究中唯一的不良反应是缓释丁丙诺啡注射部位出现轻度红斑反应。
